Business Description
Evotec SE
ISIN : DE0005664809
Compare
Compare
Traded in other countries / regions
EVT.Germany0IRF.UKEVO.USA1EVT.ItalyEVT.BulgariaEVT.Austria IPO Date
2021-07-05Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | -7.03 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.7 | |||||
| 3-Year EBITDA Growth Rate | -38.6 | |||||
| 3-Year FCF Growth Rate | -42.2 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 15.28 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.48 | |||||
| 9-Day RSI | 71.71 | |||||
| 14-Day RSI | 70.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.79 | |||||
| Cash Ratio | 1.17 | |||||
| Days Inventory | 18.73 | |||||
| Days Sales Outstanding | 64.71 | |||||
| Days Payable | 64.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -7.65 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 20.16 | |||||
| Operating Margin % | -10.09 | |||||
| Net Margin % | -11.68 | |||||
| FCF Margin % | -28.96 | |||||
| ROE % | -7.99 | |||||
| ROA % | -4.02 | |||||
| ROIC % | -4.2 | |||||
| ROC (Joel Greenblatt) % | -11.45 | |||||
| ROCE % | -4.97 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 192.31 | |||||
| Shiller PE Ratio | 61.01 | |||||
| PS Ratio | 2.02 | |||||
| PB Ratio | 1.42 | |||||
| Price-to-Tangible-Book | 1.94 | |||||
| EV-to-EBIT | -18.83 | |||||
| EV-to-Forward-EBIT | 68.56 | |||||
| EV-to-EBITDA | -18.83 | |||||
| EV-to-Forward-EBITDA | 14.27 | |||||
| EV-to-Revenue | 2.16 | |||||
| EV-to-Forward-Revenue | 1.84 | |||||
| EV-to-FCF | -7.49 | |||||
| Price-to-Projected-FCF | 2.71 | |||||
| Price-to-Median-PS-Value | 0.3 | |||||
| Earnings Yield (Greenblatt) % | -5.31 | |||||
| FCF Yield % | -14.28 | |||||
| Forward Rate of Return (Yacktman) % | 23.21 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers